• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Parylene Coatings for Medical Device Technologies

    The Big Shift: Nearshoring Trends in Medtech Manufacturing

    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    EchoNous Partners with Samsung

    Solid Growth Forecast for Global Ostomy Devices Market

    KA Imaging's Reveal 35C Images Increase Lung Lesion Visibility

    Respira Technologies Appoints Brian Quigley as CEO

    Nikki Troiano Gainey Joins RIVANNA Board
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Parylene Coatings for Medical Device Technologies

    The Big Shift: Nearshoring Trends in Medtech Manufacturing

    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Cooling and Melting the Pain Away

    What Are the Fundamentals of Go-To-Market Strategy in Medical Devices?

    Minding the Gap: How Harmonizing Quality Systems Pays Off

    Building Strong Partnerships Between Medtech and Surgeon-Learning Platforms

    Four Key Considerations for OEMs Transferring a Product Program
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Fusion Biotec Inc.

    BMP Medical

    Arthur G. Russell Co. Inc., The

    JBC Technologies

    Cirtec Medical
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Buyer and Seller Tips on Mergers & Acquisitions for MPO Companies

    Medical Computing: COM Express Processes Real-Time Data at the Edge

    The Importance of Building Successful Supplier Relationships

    The Benefits of Outsourcing Innovation in Medtech Manufacturing

    Patching Healthcare Cybersecurity Risks in the Internet of Medical Things
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Fusion Biotec Inc.

    BMP Medical

    Arthur G. Russell Co. Inc., The

    JBC Technologies

    Cirtec Medical
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Meeting Cardiac Stent Market Needs

    Biotronik's PK Papyrus device was developed to provide physicians with a reliable covered stent that can be quickly deployed.

    Meeting Cardiac Stent Market Needs
    The PK Papyrus stent, the first device in 17 approved by the FDA to treat acute coronary perforations. Image courtesy of Biotronik.
    Related CONTENT
    • Room for Improvement in Cardiac Stent Development
    • FDA Aims to Prevent Shortages Following Sterilization Shutdowns
    • FDA to Modernize Mammography Services and Improve Their Quality
    • FDA Warns J&J and Sientra for Breast Implant Compliance Failure
    • FDA Approves Industry's Smallest, Slimmest 3T Tachycardia Devices from BIOTRONIK
    Michael Barbella, Managing Editor04.04.19
    Cardiac stents have evolved tremendously since their birth in the late 1970s, having saved and improved the lives of countless heart attack and stroke patients. These devices also help boost kidney function, enhance lower-limb blood flow, and mitigate necessary leg amputations from gangrene.
     
    Despite their many benefits, however, stents nonetheless maintain a major Achilles Heel: restenosis—i.e., recurring arterial narrowing after corrective surgery. The problem has improved significantly over the last several decades but still affects 5-7 percent of peripheral artery disease convalescents.
     
    Technology is largely responsible for the drop in restenosis rates thanks to advancements in bare metal and drug-eluting stents (DES). The latter devices were developed to overcome the limitations of their metal predecessors, namely neointimal hyperplasia, repeat revascularization, and late stent thrombosis. The latest DES are designed to produce solid long-term clinical results and minimize both restenosis and stent thrombosis rates.
     
    MPO’s March feature story “Free Flow” provides an in-depth look at the latest cardiac stent technologies and the future prospects for this burgeoning market. Dr. Alexander Uhl, senior vice president of Corporate Marketing at Biotronik, was among the experts interviewed for the feature; his full input is provided in the following Q&A.

    Michael Barbella: Why did Biotronik design a covered coronary stent system (the first approved in 17 years)? What challenges were involved in developing the stent, and what kinds of market advantages does it provide for Biotronik?
    Dr. Alexander Uhl: Biotronik continues to invest in bringing a full range of innovative coronary vascular intervention (CVI) products to the U.S. market, and the PK Papyrus is a unique, life-saving technology that is an important part of this portfolio. We invested in the development of PK Papyrus to meet a critical need in interventional cardiology. While coronary artery perforation is very uncommon—less than 4,000 per year in the United States—physicians must be fully prepared for this emergency event in order to save lives. When a perforation occurs during a percutaneous coronary intervention (PCI) procedure, physicians need a reliable covered stent that can be deployed quickly. Designed to deliver when seconds count, PK Papyrus is engineered on a single-stent, ultrathin strut platform that makes it more flexible and gives it a low crossing profile. Because of these features, PK Papyrus delivers more like a conventional stent with 5 French compatibility. We've improved every aspect of previous covered stents, transforming what was once a dreaded emergency use device into a reliable solution that physicians can deploy with confidence in critical situations.
    PK Papyrus was approved for distribution by the FDA in September 2018 and has been trusted in international markets since receiving CE Marking in 2013. We made the decision to invest in PK Papyrus because patient care is paramount and Biotronik is committed to helping physicians and hospitals save lives and improve patient outcomes.

    Barbella: What trends are impacting the coronary stent market? What factor(s) are driving these trends?
    Dr. Uhl: As a private, independent company, Biotronik answers to values that dictate excellence and reliability before short-term gains. In the U.S. market, hospitals and health systems continue to leverage bargaining power and negotiate with vendors, driving consolidation amongst industry. The interventional cardiology market is also specifically affected by the growing focus on value-based care and long-term outcomes, which has brought changes in reimbursement policies, more intentional selection of PCI candidates, and various institutional cost-containment measures. Regardless of the market landscape, Biotronik focuses on proven, safe, and reliable solutions that demonstrate our commitment to care and foster relationships built on trust. We remain private by choice and are committed to partnering with hospitals to address the mounting cost pressures they're facing, which demand uncompromised quality.
    Drug-eluting stents (DES) are used in more than 95 percent of all PCI procedures, with the occasional use of bare-metal stents (BMS) like Biotronik's PRO-Kinetic Energy. Because of the excellent clinical outcomes many modern DES have achieved, there has been commoditization in this space in the past decade that has made cost a primary driver for health system decision-makers. However, the BIOFLOW-V pivotal trial shows Biotronik's ultrathin Orsiro DES has demonstrated sustained improvement over Xience at multiple clinical endpoints. Orsiro's unprecedented outcomes may shift the market back toward a greater focus on clinical data.

    Barbella: What factors are currently driving growth in the coronary vascular intervention market? How have these growth factors evolved over the past five years?
    Dr. Uhl: Biotronik has been a player in the global vascular intervention space since 1994. In early 2017, we introduced our CVI portfolio to the United States with the launch of the PRO-Kinetic Energy and followed that with the approval of PK Papyrus in 2018. This market has remained largely stable over the past five years, with physicians performing approximately 950,000 PCI procedures annually. Future growth could be driven by an aging population and correlations to general lifestyle factors that may lead to coronary artery disease. 
    In alignment with value-based care, the decision-making process in many medtech sectors has evolved from physician preference or lowest cost to a discussion of positive patient outcomes and quality of care measures. Though PCI procedure volume is steady, the commoditization of the CVI market due to near-equivalent outcomes data has been eroding the average selling price (ASP) by approximately 10 percent year over year, causing a decline in total market value.
    The U.S. DES market has suffered for too long from a lack of innovation. Patients deserve better outcomes, physicians deserve better performance, and healthcare administrators deserve more options. With Biotronik leading the way through meaningful innovations such as ultrathin struts and improved biocompatibility, the CVI market may refocus on clinical outcomes as the primary driving factor.

    Barbella: What challenges are involved in developing a coronary stent? How has Biotronik overcome these challenges?
    Dr. Uhl: Biotronik is a well-respected leader in CVI solutions outside the United States, where the value of our global portfolio has been recognized by the interventional cardiology community around the world. Our solutions have been proven in international markets and it made sense to invest in bringing these proven solutions to the United States as well. This is a market that rewards innovation and we are one of the most innovative companies the enter the CVI space in a long time. Stent research, design, manufacturing, and the clinical studies required to bring them to the U.S. market require decades of dedication and millions of dollars in capital investment. Biotronik has developed this technology for 25 years and optimized metallic stent design with the engineering of our ultrathin strut, cobalt chromium, double helix—the foundation on which we build our bare-metal, drug-eluting, and covered stents. We continue to invest in new technologies designed to help physicians improve patient care and ensure better outcomes. PK Papyrus and Orsiro are examples of Biotronik's continued investment.

    Barbella: How is value-based care, new technologies like artificial intelligence, and material innovations affecting stent product designs?
    Dr. Uhl: Value-based care is the natural extension of proven solutions with strong clinical outcomes. At Biotronik, we never rush to market. We research, innovate, and develop, then significantly invest in clinical studies to prove the capabilities of our products. Physicians trust Biotronik and know that our solutions will deliver reliable outcomes. In today's healthcare environment, that is the foundation of creating value. Clinical evidence has demostrated that Orsiro improves outcomes in comparison to Xience and Resolute; outcomes data is what really matters when creating and embracing value-based care.
    Biotronik is the only company to manufacture a magnesium-based scaffold technology—the Magmaris Resorbable Magnesium Scaffold—which is available in CE and other international markets today. This materials innovation enables Magmaris to deliver and expand more like a conventional DES. Outcomes data from the BIOSOLVE-II and BIOSOLVE-III clinical studies show zero percent scaffold thrombosis at two years. These studies are investigating the safety and efficacy of Biotronik's Magmaris resorbable magnesium scaffold in Europe, South America, and Asia. Magmaris is not currently available in the United States.

    Barbella: What new stent technologies are up and coming/on the horizon? What new stent technologies can we expect to see in the next several years?
    Dr. Uhl: Resorbable scaffolds and polymer-free DES are currently available in CE markets. As investigators continue to conduct clinical trials and report their results, we may see those technologies enter the U.S. market as well.  
    Related Searches
    • patient
    • healthcare
    • stroke
    • technologies
    Related Knowledge Center
    • Cardiovascular
    Suggested For You
    Room for Improvement in Cardiac Stent Development Room for Improvement in Cardiac Stent Development
    FDA Aims to Prevent Shortages Following Sterilization Shutdowns FDA Aims to Prevent Shortages Following Sterilization Shutdowns
    FDA to Modernize Mammography Services and Improve Their Quality FDA to Modernize Mammography Services and Improve Their Quality
    FDA Warns J&J and Sientra for Breast Implant Compliance Failure FDA Warns J&J and Sientra for Breast Implant Compliance Failure
    FDA Approves Industry FDA Approves Industry's Smallest, Slimmest 3T Tachycardia Devices from BIOTRONIK
    Cardiac Stent Feature Trailer 2019 Cardiac Stent Feature Trailer 2019
    FDA to Closely Examine Surgical Stapler Risks FDA to Closely Examine Surgical Stapler Risks
    Free Flow: A Look at the Current State of Stents Free Flow: A Look at the Current State of Stents
    Saranas Saranas' Early Bird Bleed Monitoring System Gains De Novo Clearance
    FDA Commissioner Scott Gottlieb to Step Down FDA Commissioner Scott Gottlieb to Step Down
    Medtronic Medtronic's Resolute DES Platform Gains FDA Nod for Chronic Total Occlusion
    Help Wanted Help Wanted
    Design Sophisticate Design Sophisticate
    Connected R&D Connected R&D
    Small Steps Small Steps

    Related Online Exclusives

    • Cardiovascular
      Room for Improvement in Cardiac Stent Development

      Room for Improvement in Cardiac Stent Development

      Less-than-optimal outcomes will drive future growth in the global stent market.
      Michael Barbella, Managing Editor 03.29.19

    • Packaging & Sterilization
      FDA Aims to Prevent Shortages Following Sterilization Shutdowns

      FDA Aims to Prevent Shortages Following Sterilization Shutdowns

      The agency will work to ensure safe and effective sterilization amid the shutdown of a large contract sterilization facility and the planned shutdown of another.
      U.S. Food and Drug Administration 03.27.19

    • Diagnostics
      FDA to Modernize Mammography Services and Improve Their Quality

      FDA to Modernize Mammography Services and Improve Their Quality

      Proposed rule would require breast density reporting, enhance the FDA’s ability to enforce mammography facilities’ compliance with standards.
      U.S. Food and Drug Administration 03.27.19


    • Surgical
      FDA Warns J&J and Sientra for Breast Implant Compliance Failure

      FDA Warns J&J and Sientra for Breast Implant Compliance Failure

      The two breast implant manufacturers failed to comply with post-approval study requirements.
      U.S. Food and Drug Administration 03.20.19

    • Cardiovascular
      FDA Approves Industry

      FDA Approves Industry's Smallest, Slimmest 3T Tachycardia Devices from BIOTRONIK

      Long-lasting devices feature unique DX technology and enhanced automation of heart failure therapy.
      PR Newswire 03.15.19

    Loading, Please Wait..

    Trending
    • Monkeypox Outbreak Driving New IVD Device Development
    • M1 MedTech Announces Fall 2022 Cohort
    • Preceptis Medical’s Tympanostomy Tube System Cleared For Expanded Indications
    • Pulsed Field Ablation Tech Gaining Popularity
    • Edwards' PASCAL Precision Gains EU Nod
    Breaking News
    • EchoNous Partners with Samsung
    • Solid Growth Forecast for Global Ostomy Devices Market
    • KA Imaging's Reveal 35C Images Increase Lung Lesion Visibility
    • Respira Technologies Appoints Brian Quigley as CEO
    • Nikki Troiano Gainey Joins RIVANNA Board
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Parylene Coatings for Medical Device Technologies
    • Nearshoring Trends in Medtech Manufacturing
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFIC 2022 Food & Health Survey Highlights Eating Behavior Trends
    Icon Foods Appoints Operations and Marketing Leaders
    Annatto Tocotrienol Shown to Improve Weight Loss and Inflammation Markers in Patients with NAFLD
    Coatings World

    Latest Breaking News From Coatings World

    Birla Carbon, NREL Collaboration to be Presented at ACS Conference
    Coating Resins Market Worth $70.9 Billion by 2027: MarketsandMarkets
    PPG Appoints Brad Budde Vice President and Chief Digital Officer
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Partners with Samsung
    Solid Growth Forecast for Global Ostomy Devices Market
    KA Imaging's Reveal 35C Images Increase Lung Lesion Visibility
    Contract Pharma

    Latest Breaking News From Contract Pharma

    GRAM to Fill and Finish Smallpox/Monkeypox Vaccines
    bluebird bio Wins FDA Approval of ZYNTEGLO
    Pace Life Sciences Acquires Meridian BioGroup
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Sephora at Kohl’s to Expand Sephora Presence to All 1,100+ Kohl’s Locations
    Emma Watson to Front New Fragrance Campaign for Prada
    The Estée Lauder Companies Delivers Strong Results in Fiscal 2022
    Happi

    Latest Breaking News From Happi

    Amorepacific, MIT Develop World's First Chip-less Wireless Electronic Skin Enabled by Semiconductors
    Maesa Launches Itk Skincare with TikTok Stars Brooklyn and Bailey McKnight
    Skin Delivery Formulation
    Ink World

    Latest Breaking News From Ink World

    Xeikon to Introduce TITON Food-Safe Dry-Toner Technology at Labelexpo Americas 2022
    Smurfit Kappa Employees Charity Cycle Across Europe
    ProAmpac’s Rocky Mount, VA Facility Receives ISCC Plus Certification
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    ePac makes big announcement, Avery Dennison debuts new technology and more
    Techkon USA announces latest handheld spectrodensitometer
    Maxcess China now manufacturing solid dies in Huzhou
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    INDA Appoints Director of Membership and Industry Relations
    Nexwear Acquires Incontinence Products Brand Lily Bird
    Because Market Expands into Retail Stores
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Theragen Receives Patent for Spine Fusion Bone Growth Stimulator System
    Study: BONESUPPORT’s CERAMENT G Can Help Save Infected Limbs
    Zavation’s Cervical Intervertebral Body Fusion Device Cleared by FDA
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    NREL, Birla Carbon Collaboration to be Shown at ACS Conference
    ORNL Celebrates Launch of Frontier, the World’s Fastest Supercomputer
    DuPont Names 2022 Lavoisier and Pedersen Award Medalists

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login